Home
Stocks
AdAlta Ltd.
Filings
AdAlta Ltd. (FWB:JDA) Filings
AdAlta Ltd.
Filings
Filing
Date
Type
Filed with
EW-001 Orphan Drug Designation, pre-IND update
Nov 16, 2026
Operations update
ASX
$1.4m additional RDTI refund
Nov 11, 2026
Results
ASX
Letter to Shareholders, Notice of AGM & Proxy Form
Oct 29, 2026
Meeting notice
ASX
Change of AGM Date
Oct 27, 2026
Meeting notice
ASX
Quarterly Appendix 4C and Activities Report
Oct 25, 2026
Quarterly report
ASX
RDTI receipt, Advanced Overseas Finding
Oct 18, 2026
Results
ASX
RDTI receipt, Advanced Overseas Finding
Oct 18, 2026
Results
ASX
EW-001 JDC milestone approvals
Oct 4, 2026
Other filings
ASX
China Representative Office opens
Sep 30, 2026
Operations update
ASX
Date of AGM & Closing Date for Director Nominations
Sep 29, 2026
Meeting notice
ASX
US FDA grants EW-001 pre-IND meeting
Sep 22, 2026
Operations update
ASX
Oribiotech deal validates AdAlta manufacturing strategy
Sep 17, 2026
Operations update
ASX
CAR-TCR Summit poster
Sep 14, 2026
Operations update
ASX
Bilingual BIOSeedin Investor Presentation
Sep 9, 2026
Operations update
ASX
BZDS1901 special access scheme launch in China
Sep 1, 2026
Operations update
ASX
Appendix 4G and Corporate Governance Statement
Aug 21, 2026
Other filings
ASX
Annual Report to shareholders
Aug 21, 2026
Annual report
ASX
Preliminary Final Report
Aug 21, 2026
Results
ASX
Investor presentation
Aug 12, 2026
Other filings
ASX
EW-001 IIT study overall survival update
Aug 9, 2026
Other filings
ASX
2 year survival milestone for EW-001 patient
Aug 4, 2026
Other filings
ASX
Quarterly Appendix 4C and Activities Report
Jul 28, 2026
Quarterly report
ASX
Oktopi AI collaboration for research efficiency
Jul 1, 2026
Operations update
ASX
Second BZDS1901 milestone paid
Jun 30, 2026
Other filings
ASX
Regulatory advisors appointed for BZDS1901
May 24, 2026
Operations update
ASX
$2.5m placement
May 4, 2026
Financing
ASX
BZDS1901 manufacturing agreement
Apr 28, 2026
Other filings
ASX
Automated cell therapy manufacturing MoU
Apr 20, 2026
Operations update
ASX
BZDS1901 clinical update
Mar 31, 2026
Other filings
ASX
AdCella and SHcell hold first JDC meeting
Mar 26, 2026
Operations update
ASX
New AD-214 patent granted
Mar 19, 2026
Other filings
ASX
AdCella expands clinical advisory board
Mar 3, 2026
Other filings
ASX
AdCella Clinical Advisory Board convened
Feb 25, 2026
Other filings
ASX
Half Yearly Report and Accounts
Feb 19, 2026
Interim report
ASX
Quarterly Appendix 4C and Activities Report
Jan 29, 2026
Quarterly report
ASX
AdCella milestones and regulatory progress
Jan 20, 2026
Operations update
ASX
Placement raises A$1.2 million
Jan 12, 2026
Financing
ASX
CAR-T collaboration agreement
Jan 1, 2026
Operations update
ASX
$0.78 million FY25 RDTI refund received
Dec 3, 2025
Results
ASX
AGM share consolidation resolution withdrawal
Nov 6, 2025
Meeting outcome
ASX
Meurs Group Investment Agreement Update
Oct 27, 2025
Financing
ASX
NLSC investment balance repaid
Oct 23, 2025
Financing
ASX
Letter to Shareholders, Notice of AGM & Proxy Form
Oct 23, 2025
Meeting notice
ASX
At market Placement raises additional up to A$1.1 million
Oct 19, 2025
Financing
ASX
Placement raises up to A$0.5 million and transaction update
Oct 12, 2025
Financing
ASX
Preliminary Final Report
Aug 26, 2025
Results
ASX
Investor Presentation - TechKnow Invest Roadshow
Aug 18, 2025
Other filings
ASX
Renounceable Rights Issue shortfall placed
Jun 12, 2025
Financing
ASX
Rights Issue raises $1.1million
Jun 2, 2025
Financing
ASX
Notice of change of exercise price of options
May 28, 2025
Other filings
ASX
Prospectus
May 4, 2025
Offer document
ASX
Renounceable Rights Issue to Raise up to $1.3 million
May 1, 2025
Financing
ASX
Trading Halt
Apr 29, 2025
Trading halt or suspension
ASX
SYNBV invest up to $2m in East to West subsidiary
Mar 19, 2025
Financing
ASX
R&D Tax Incentive advance received
Mar 4, 2025
Other filings
ASX
Investor Presentation
Feb 6, 2025
Other filings
ASX
East to West cell therapy strategy update
Feb 5, 2025
Operations update
ASX
AD-214 clinical advisory board
Oct 9, 2024
Other filings
ASX
FY24 RDTI Refund Received $1.77m
Oct 3, 2024
Results
ASX
Transaction, investment facility update
Sep 2, 2024
Financing
ASX
$1.9 million raised from exercise of 1ADOA options
Jun 2, 2024
Financing
ASX
Cellular immunotherapy manufacturer secured - Cell Therapies
May 12, 2024
Operations update
ASX
Extension of Victorian Government RDTI Loan Facility
Apr 28, 2024
Financing
ASX
Institutional investment to pursue strategic initiatives
Apr 28, 2024
Financing
ASX
SYNBV MoU Webinar presentation
Apr 9, 2024
Other filings
ASX
SYNThesis BioVentures MoU for cellular immunotherapies
Apr 7, 2024
Operations update
ASX
Corporate Presentation
Mar 7, 2024
Other filings
ASX
Positive AD-214 Phase I extension study results
Mar 5, 2024
Other filings
ASX
January 2024 partnering presentations and progress
Jan 21, 2024
Other filings
ASX
New malaria inhibiting i-body
Dec 18, 2023
Other filings
ASX
Chair address and CEO presentation to AGM
Nov 21, 2023
Annual report
ASX
AD-214 Phase I extension clinical study - interim results
Nov 20, 2023
Results
ASX
Oversubscribed placement result
Nov 6, 2023
Financing
ASX
Placement to raise up to $1.23million
Nov 2, 2023
Financing
ASX
AD-214 well tolerated in Phase I extension study
Oct 22, 2023
Operations update
ASX
R&D tax refund received & R&D Loan repayment terms extended
Oct 17, 2023
Financing
ASX
Prof Foley invited presentation AD-214
Sep 25, 2023
Other filings
ASX
Dosing simulations support AD-214 IV product profile
Sep 24, 2023
Other filings
ASX
AD-214 Phase I extension study fully enrolled
Sep 19, 2023
Other filings
ASX
AD-214 returns to clinic
Aug 3, 2023
Other filings
ASX
$1.87 million raised in oversubscribed Shortfall facility
Jul 12, 2023
Other filings
ASX
New AD-214 data de-risks clinical studies
Jul 6, 2023
Other filings
ASX
AD-214 clinical trial approval
Jun 28, 2023
Other filings
ASX
Rights Offer results
May 24, 2023
Other filings
ASX
Rights Offer to fund early return to clinic and growth
Apr 27, 2023
Other filings
ASX
Publication highlights I-body potential in osteoporosis
Jan 24, 2023
Other filings
ASX
AdAlta welcomes new substantial shareholders
Jan 23, 2023
Other filings
ASX
Second Japan patent for AD-214
Jan 9, 2023
Other filings
ASX
AD-214 progress and priorities webinar presentation
Nov 1, 2022
Other filings
ASX
AD-214 progress and priorities
Nov 1, 2022
Other filings
ASX
Balance of R&D Tax Incentive Refund received
Oct 26, 2022
Other filings
ASX
1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer
Oct 12, 2022
Other filings
ASX
R&D Tax Incentive Refund received
Oct 3, 2022
Other filings
ASX
AD-214 program update, cash runway extension
Jul 3, 2022
Other filings
ASX
European Patent for AD-214 granted
Jun 13, 2022
Other filings
ASX
BIO International Convention presentation
May 31, 2022
Other filings
ASX
AdAlta presentation at Bioshares Biotech Summit
May 9, 2022
Other filings
ASX
Indian patent for AD-214
Apr 6, 2022
Other filings
ASX
Inhaled AD-214 preclinical program
Apr 4, 2022
Other filings
ASX
PAC Partners Healthcare Conference - Corporate Presentation
Apr 4, 2022
Other filings
ASX
$1.6M Second Tranche R&D Cash Flow Loan Received
Mar 8, 2022
Other filings
ASX
Chinese patent granted for AD-214
Mar 1, 2022
Other filings
ASX
Entitlement Offer Results
Feb 3, 2022
Financing
ASX
Entitlement Offer Booklet
Dec 22, 2021
Financing
ASX
Reinstatement to Quotation
Dec 14, 2021
Trading halt or suspension
ASX
Voluntary Suspension
Dec 13, 2021
Trading halt or suspension
ASX
Inhaled AD-214 passes first development milestone
Dec 8, 2021
Other filings
ASX
AGM presentations & first iCAR-T data
Nov 28, 2021
Other filings
ASX
Second US patent for AD-214
Nov 17, 2021
Other filings
ASX
BTB funding transferred to AD-214 inhalation program
Oct 6, 2021
Other filings
ASX
New pre-clinical data presented at Boston conference
Sep 26, 2021
Other filings
ASX
Corporate overview and IRD Invest 2021 presentation
Sep 20, 2021
Other filings
ASX
$4.0M Non-Dilutive Financing with Victorian Government
Sep 19, 2021
Other filings
ASX
Carina collaboration webinar presentation
Aug 25, 2021
Other filings
ASX
CAR-T collaboration with Carina Biotech
Aug 23, 2021
Other filings
ASX
Webinar and presentation on AD-214 strategy
Jul 19, 2021
Other filings
ASX
AD-214 pathway to IPF efficacy studies
Jul 18, 2021
Other filings
ASX
AdAlta secures AD-214 resupply
Jul 1, 2021
Other filings
ASX
R&D Tax Incentive Facility
Jun 24, 2021
Other filings
ASX
GE Healthcare collaboration advances to next stage
May 23, 2021
Other filings
ASX
AdAlta granted Japanese patent for AD-214
May 18, 2021
Other filings
ASX
Mutiple Dose Part Of Ad-214 Phase I Trial Commenced
Apr 18, 2021
Other filings
ASX
Investor briefing-AD-214 top line single dose safety results
Mar 9, 2021
Other filings
ASX
Appendix 4D and Interim Financial Report
Feb 25, 2021
Interim report
ASX
FDA Orphan Drug Designation for AD-214
Feb 23, 2021
Other filings
ASX
Phase I HV extension to explore encouraging results
Dec 13, 2020
Other filings
ASX
AGM Presentation
Nov 25, 2020
Other filings
ASX
AusBiotech presentation including Phase I status update
Oct 26, 2020
Other filings
ASX
Investor Presentation - BIO investor forum
Oct 9, 2020
Other filings
ASX
GE Healthcare collaboration progresses
Sep 20, 2020
Other filings
ASX
Non-renounceable Rights Issue Offer
Aug 18, 2020
Financing
ASX
Placement and Rights Offer
Aug 10, 2020
Financing
ASX
Investor presentation including future milestones
Jul 29, 2020
Other filings
ASX
First participants treated in AD-214 Phase I trial
Jul 23, 2020
Other filings
ASX
Supportive US FDA pre-IND meeting results for AD-214
Jul 19, 2020
Other filings
ASX
AdAlta receives approval to commence AD-214 Phase I trial
Jun 9, 2020
Other filings
ASX
Business update and COVID-19 response
Mar 30, 2020
Operations update
ASX
Board changes and R&D Tax Incentive advance received
Mar 26, 2020
Other filings
ASX
Investor Briefing - Strategic Plan
Mar 2, 2020
Other filings
ASX
AD-214 effective in gold standard pre-clinical animal model
Mar 1, 2020
Other filings
ASX
Appendix 4C - quarterly
Jan 30, 2020
Quarterly report
ASX
AdAlta Granted US Patent for AD-214
Jan 29, 2020
Other filings
ASX
AD-214 Phase I strategy and timing update
Jan 13, 2020
Other filings
ASX
AdAlta awarded Biomedical Translation Bridge Funding
Dec 12, 2019
Other filings
ASX
GLP Toxicology study results
Oct 28, 2019
Other filings
ASX
Tim Oldham Appointed as Chief Executive Officer
Oct 8, 2019
Other filings
ASX
Receipt of R&D Tax Incentive
Sep 17, 2019
Other filings
ASX
AdAlta secures licensing deal with GE Healthcare
Sep 15, 2019
Other filings
ASX
Executive team changes
Aug 11, 2019
Other filings
ASX
GLP toxicology study commences
Jul 15, 2019
Other filings
ASX
Entitlement Offer Results and Shortfall Notification
Jun 14, 2019
Financing
ASX
Completion of Capital Raise - $5 million
May 23, 2019
Other filings
ASX
AD-214 manufacturing update
May 2, 2019
Other filings
ASX
Manufacturing update
Jan 28, 2019
Other filings
ASX
Appendix 4C - Quarter ended 30 September 2018
Oct 16, 2018
Quarterly report
ASX
Manufacturing Update
Oct 14, 2018
Other filings
ASX
Change of Registry Address: Automic P/L - Sydney Office
Sep 28, 2018
Other filings
ASX
Investor presentation and conference call
Jul 31, 2018
Other filings
ASX
Appendix 4C - Quarter ended 30 June 2018
Jul 15, 2018
Quarterly report
ASX
Completion of Capital Raise - $4.25m to advance AD-214
Jul 12, 2018
Other filings
ASX
AdAlta secures key manufacturing agreements for AD-214
Jun 4, 2018
Other filings
ASX
Appendix 4C - Quarter Ended 31 March 2018
Apr 22, 2018
Quarterly report
ASX
AdAlta to advance improved lung fibrosis therapy, AD-214
Apr 17, 2018
Other filings
ASX
AdAlta collaborator awarded NHMRC grant
Dec 6, 2017
Other filings
ASX
AdAlta granted key Australian Patent
Nov 16, 2017
Other filings
ASX
Commercial agreement with XL-protein
Nov 13, 2017
Other filings
ASX
Conference Presentation
Oct 31, 2017
Other filings
ASX
Results of multi-dose toxicology study
Sep 18, 2017
Other filings
ASX
AdAlta awarded SIEF grant
Jul 23, 2017
Other filings
ASX
Toxicology study and manufacturing update
Jul 17, 2017
Other filings
ASX
Presentation of Eye Fobrosis Data at ARVO Meeting
May 8, 2017
Other filings
ASX
AdAlta expands partnership with Alfred Hospital
Mar 20, 2017
Other filings
ASX
AdAlta receives Orphan Designation for AD-114
Jan 18, 2017
Other filings
ASX
Positive Pre-clinical Data
Jan 8, 2017
Other filings
ASX
Commercialisation Agreement with Crossbeta Biosciences
Nov 7, 2016
Other filings
ASX
Quarterly Review and Appendix 4C
Oct 26, 2016
Quarterly report
ASX
Receipt of Innovation Connections Grant
Sep 13, 2016
Other filings
ASX
Agreement with FujiFilm Diosynth Biotechnologies
Sep 12, 2016
Other filings
ASX